Bugworks Research is a clinical-stage biopharmaceutical company focused on developing innovative therapies to combat infectious diseases and cancer. The company is actively engaged in the discovery of next-generation oncology therapeutics, aiming to create affordable small molecule treatments for difficult-to-treat tumors. Their research emphasizes the need for new antibacterial agents to address the growing threat of antimicrobial resistance (AMR). Bugworks is developing proprietary agents that target a wide range of priority pathogens, including those resistant to current treatments, and aims to provide both intravenous and oral options for treating various infections.

The company's pipeline includes several promising candidates, such as BWC0977, which is designed to treat critical care infections, and BWC2094, targeting the adenosine pathway implicated in various cancers. Bugworks employs sophisticated technologies to enhance the efficacy of their therapeutics, including small molecule approaches that can modulate the immune system, potentially working synergistically with existing biologic therapies. Their commitment to addressing significant health challenges is underscored by a team with extensive experience in drug discovery and development, collaborating with global partners to advance their innovative solutions.

India

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity.

Bugworks Research

Company Details